Alnylam Pharmaceuticals, Inc. ALNY

Company Overview

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics, a technology that silences disease-causing genes at the messenger RNA level. The company operates primarily within the biotechnology and pharmaceutical industries, with a concentration on genetic, cardiometabolic, hepatic, and rare diseases. Alnylam’s revenue is driven mainly by product sales of its approved RNAi-based medicines and, to a lesser extent, collaboration and royalty revenue.

Founded in 2002, Alnylam was among the earliest companies to commercialize RNAi technology and has played a central role in establishing RNAi as a validated therapeutic modality. The company achieved a major milestone with the first-ever FDA approval of an RNAi therapeutic in 2018, marking its transition from a research-focused organization to a fully integrated commercial-stage biopharmaceutical company. Its strategic advantage lies in its proprietary RNAi delivery platforms and deep intellectual property portfolio, which underpin multiple approved therapies and a broad clinical pipeline.